/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Serina Therapeutics Inc share price today is $1.56, up 4%. The stock opened at $1.5 against the previous close of $1.5, with an intraday high of $1.56 and low of $1.445.

style

pb-0

Serina Therapeutics Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$1.56 0.04(4%) SER at 13 Mar 2026 03:11 PM Biotechnology

Lowest Today 1.445

Highest Today 1.56

Today’s Open 1.5

Prev. Close 1.5

52 Week High 7.92

52 Week Low 1.42

Day’s Range: Low 1.445 High 1.56

52-Week Range: Low 1.42 High 7.92

Serina Therapeutics Inc Institutional Holdings

Serina Therapeutics Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Serina Therapeutics Inc Fundamentals

Market Cap 16.18 M

PB Ratio 21.9906

PE Ratio 0.0

Enterprise Value 13.81 M

Total Assets 6.72 M

Volume 59945

Serina Therapeutics Inc Company Financials

Annual Revenue FY23:142000 0.1M

Annual Profit FY23:-29000 -0.0M

Annual Net worth FY23:-14803000 -14.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:130000 0.1M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:51000 0.1M

Quarterly Profit Q3/2025:-17000 -0.0M, Q2/2025:114000 0.1M, Q1/2025:-17000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-6000 -0.0M

Quarterly Net worth Q3/2025:-4585000 -4.6M, Q2/2025:-6448000 -6.4M, Q1/2025:-4813000 -4.8M, Q3/2024:1410000 1.4M, Q2/2024:5204000 5.2M

About Serina Therapeutics Inc & investment objective

Company Information Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Organisation Biotechnology

Employees 12

Industry Biotechnology

CEO Mr. Steven A. Ledger

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*